The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways
Authors
Keywords
Stromal cells, Apoptosis, Polyphosphoinositide signaling cascade, Flow cytometry, Cell staining, Hematology, JAK-STAT signaling cascade, Transcription factors
Journal
PLoS One
Volume 10, Issue 12, Pages e0143897
Publisher
Public Library of Science (PLoS)
Online
2015-12-02
DOI
10.1371/journal.pone.0143897
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms
- (2015) Ruchi Pandey et al. Molecular Cancer
- Sphingosine-1-Phosphate Mediates ICAM-1-Dependent Monocyte Adhesion through p38 MAPK and p42/p44 MAPK-Dependent Akt Activation
- (2015) Chih-Chung Lin et al. PLoS One
- The future of JAK inhibition in myelofibrosis and beyond
- (2014) John O. Mascarenhas et al. BLOOD REVIEWS
- Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt- -catenin signaling
- (2013) B. Zhang et al. BLOOD
- Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis
- (2013) Daniel J. DeAngelo et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia
- (2013) Christen L. Andersen et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
- (2013) Srdan Verstovsek et al. CANCER
- Histone Deacetylase Inhibitors Potentiate Vesicular Stomatitis Virus Oncolysis in Prostate Cancer Cells by Modulating NF- B-Dependent Autophagy
- (2013) L. Shulak et al. JOURNAL OF VIROLOGY
- Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells
- (2013) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells
- (2013) Ellen Weisberg et al. PLoS One
- Vorinostat Induces Apoptosis and Differentiation in Myeloid Malignancies: Genetic and Molecular Mechanisms
- (2013) Gabriela Silva et al. PLoS One
- Concise Review: Current Concepts in Bone Marrow Microenvironmental Regulation of Hematopoietic Stem and Progenitor Cells
- (2013) Julianne N. P. Smith et al. STEM CELLS
- Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy
- (2012) L. van de Laar et al. BLOOD
- Efficacy of vorinostat in a murine model of polycythemia vera
- (2012) H. Akada et al. BLOOD
- Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis
- (2012) J. Mascarenhas et al. CLINICAL CANCER RESEARCH
- Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors
- (2012) E Weisberg et al. LEUKEMIA
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- MEKK1-MKK4-JNK-AP1 Pathway Negatively Regulates Rgs4 Expression in Colonic Smooth Muscle Cells
- (2012) Yonggang Zhang et al. PLoS One
- New mutations and pathogenesis of myeloproliferative neoplasms
- (2011) W. Vainchenker et al. BLOOD
- Bone Marrow Stroma-Secreted Cytokines Protect JAK2V617F-Mutated Cells from the Effects of a JAK2 Inhibitor
- (2011) T. Manshouri et al. CANCER RESEARCH
- Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms
- (2011) Gregor Hoermann et al. FASEB JOURNAL
- The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers
- (2011) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- TAL1/SCL is downregulated upon histone deacetylase inhibition in T-cell acute lymphoblastic leukemia cells
- (2011) B A Cardoso et al. LEUKEMIA
- Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy
- (2011) Yordanos Tesfai et al. LEUKEMIA RESEARCH
- An shRNA-Based Screen of Splicing Regulators Identifies SFRS3 as a Negative Regulator of IL-1β Secretion
- (2011) Pedro Moura-Alves et al. PLoS One
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- Advances in Understanding and Management of Myeloproliferative Neoplasms
- (2009) A. M. Vannucchi et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia
- (2009) S. Park et al. HAEMATOLOGICA
- The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes
- (2008) G. Wernig et al. BLOOD
- Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
- (2008) Z. Zeng et al. BLOOD
- Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence
- (2008) J.-J. Lataillade et al. BLOOD
- The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance
- (2008) M. B. Meads et al. CLINICAL CANCER RESEARCH
- PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability
- (2008) Ana Silva et al. JOURNAL OF CLINICAL INVESTIGATION
- Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
- (2008) E. Weisberg et al. MOLECULAR CANCER THERAPEUTICS
- Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells
- (2008) Angela Colmone et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now